Oh yes, sell....with multi-million, next-gen cancer diagnostic products announced within weeks.
First update due in thirty days, sending good vibes. Incredibly exciting as both an investor and humanitarian.
Even the smallest improvement for these paralyzed patients will make a world of difference.
Triple coming. By mid 2016 I predict BTX will acquire the rest of Geron company.
n 2007 Dr. West joined as CEO and transformed it into a full blown regenerative medicine company. Before he became CEO Biotime had zero subsidiaries, no clinical trials and not one stem cell patent, basically he started Biotime from scratch. West's experience within the stem industry is nothing less than legendary, helped isolated the first hESC that lead to the cloning of 'Dolly' the sheep, formed a team that put telomerase on the map, founded Geron, started the first hESC clinical trial....quite amazing history.
Anyway, here we are in 2015 with a company built from the ground up and within eight years acquired some of the worlds leading ip within the biotech industry:
-hESC's: Geron Corporation Stem Cell Assets (October 2013)
-Genetic 'Big Data': Xennex Corporation (April 2012)
-Extra-cellular matrix ip: Glycosan BioSystems, Inc. (March 2011)
-Nano-peptide/cell targeting ip: Cell Targeting, Inc. (January 2011)
-GMP hESC manufacturing ip: ES Cell International Pte Ltd (May 2010)
So what does the future hold for BTX?
First multi-million dollar product to be introduced: PanC-DX(slated to unveiled 4Q 2015):
The BTX structure of subsidiaries was set up by Dr. West to ensure balance and long term success with the ability to cross license its huge ip estate internally. Currently Biotime's first IPO AST is on the NYSE and doing quite well. With 67% ownership BTX is using its Geron hESC ip to restart the long awaited regen spine trials. Spine preclinical's we're a success and the first patient with paralysis due to a spine injury has recently been admitted. AST also has two cancer vaccines in clinical trials. Results so far show promise.
By the end of 2015 Biotime should announce its second IPO. Chances are it will be OncoCyte(cancer subsidiary). I say this because OncoCyte will within weeks announce its cancer diagnostic product(PanC-DX) roll out. This will be a very big deal within the cancer industry and help get OncoCyte on the NYSE in no time.
So in closing, BTX in my opinion is by far the leader in the medical regen sector, and shareholders will do extremely well in 2016.
Speaking of partners, here is a list from the website:
CORPORATE PARTNERSHIPS & LICENSING
GE Healthcare (December 2014) »
Abcodia Ltd. (September 2014) »
Cancer Research UK (September 2014) »
University of Wisconsin and Louvain University (August 2014) »
Cornell University (May 2014) »
California Institute of Regenerative Medicine (May 2014) »
Jade Therapeutics (September 2013) »
University of California, Los Angeles (April 2013) »
Wistar Institute (January 2012) »
USCN Life Science, Inc. (December 2011) »
Cornell University (September 2011) »
California Institute of Regenerative Medicine (November 2010) »
Teva Pharmaceutical Industries, Ltd. (October 2010) »
Millipore (July 2009) »
Ocata Therapeutics, Inc. (formerly Advanced Cell Technology, Inc.) (July 2008) »
Wisconsin Alumni Research Foundation (January 2008) »
Hospira, Inc. (U.S.) / CJ Health Corporation (December 2006) »
CJ Health Corporation (April 2003) »
Abbott Laboratories, Inc. (April 1997) »
Should shoot up in a few weeks since we are only four months and closing before huge PanC-DX revenues start coming in. Might also be a lump sum if we partner with big pharma.
In the end, the reason that this may be a good thing for Google’s healthcare divisions is not because the conglomerate structure really provides any protection in and of itself. Having covered health care conglomerates (Life Technologies, anyone? That didn’t really work out) I’m not sure that the structure is really a good one. In what has to be a bad omen, I got a pitch from a public relations representative of stem-cell-and-longevity-focused entrepreneur Mike West saying that his current company, BioTime, presages Google’s new structure. BioTime’s market cap is just $243 million — that’s like lunch in the Alphabet cafeteria.
Moron...a $2.5 company has to be judged not on the revenues they have made but the revenues they will make.
-700+ Stem cell patents, more then any one company, institution or university worldwide.
-seven subsidiaries, AST who just ipo'd this year, has two cancer vaccines and spine regen clinical trials.
-Biotime has no debt
-Over fifteen partnerships
-3 major next-gen cancer diagnostic products to hit market in three months time
....we are under $3 a share, and you ask where are the revenues?
Option time is over, buying time has begun!
BTX cancer diagnostic PRODUCTS slated for 2015 4Q. Look for upgrade, CNBC talking heads and all major media to report on PanC-DX as being next-gen cancer test standard.
BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the first half of 2015 that are owned or licensed to BioTime or its subsidiaries. These new patents add to the portfolio of over 700 issued and pending patents and patent applications world wide that are owned or licensed to BioTime or its subsidiaries. The new patents include seven new U.S. patents, as well as 20 additional patents issued in Europe, Japan, Canada and Singapore.
Select examples of new patents issuing in the United States include:
United States patent 8,956,866 – “Retinal Pigment Epithelial Cells Differentiated from Embryonic Stem Cells with Nicotinamide and Activin A” discloses methods useful in the manufacture retinal pigment epithelial (RPE) cells such as OpRegen®, a product in clinical development by BioTime’s subsidiary, Cell Cure Neurosciences, Inc. for the treatment of the dry form of age-related macular degeneration.
United States patent 8,968,994 – “Method for Stem Cell Culture and Cells Derived Therefrom” protects the culture of pluripotent stem cells such as embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells) on positively-charged surfaces. Such surfaces are commonly used in the scale-up of pluripotent stem cells or cells made from them.
United States patent 8,951,800 – “Primate Pluripotent Stem Cell Expansion without Feeder Cells and in the Presence of FGF and Matrigel or Engelbreth-Holm-Swarm Tumor Cell Preparation” protects the culture of primate pluripotent stem cells in the presence of fibroblast growth factor and cultured on matrices such as the commonly-used product designated Matrigel.
United States patent 9,023,645 – “Isolated In Vitro Cell Population Comprising Primate Pluripotent Stem Cells Containing a Nucleic Acid Construct and Differentiated Progeny of the Pluripotent Stem Cells” claims methods useful in eliminating undifferentiated pluripotent stem cells from a product of diverse differentiated cells such as neurons, liver, or heart muscle cells.
United States patent 9,029,145 – “Chondrogenic Progenitor Cells, Protocol for Derivation of Cells and Uses Thereof” claims a method for the manufacture of cartilage cells.
United States patent 8,987,213 – “Peptides That Selectively Home to Heart Vasculature and Related Conjugates and Methods” claims a method of targeting heart vasculature for the delivery of therapeutics.
United States patent 9,062,289 – “Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells” claims methods for the manufacture of heart muscle cells (cardiomyocytes
Sounds like your options didn't clear yet, better get on board before we shoot to the moon jetbuyandsellpro.
Biotimes 700+ patents are the cream of the crop up in the regenerative sector. Dr. West has spent a life time to achieve this and will likely see him keep all ip until its value has seen light of day. Starting next year BTX will have cancer diagnostic product PanC-DX on market and the money will start pouring in, this will help fund their other many regen therapies, cancer vaccines, etc and within a few years ip will clearly be worth billions.
At that point Google can buy us and we will see a 100 fold increase!
When news breaks of this next gen cancer tests(for lung/breast/bladder) we will see a triple within days.
Just bought more BTX, chance of a life time to get in with the leader of regenerative medicine. Easy double within four months, 4X after PanC-DX announced in December.
What would revenues be roughly and what would upfront milestone payments be like for such cutting edge breast, bladder and lung cancer products?